[go: up one dir, main page]

HRP20231458T1 - Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima - Google Patents

Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima Download PDF

Info

Publication number
HRP20231458T1
HRP20231458T1 HRP20231458TT HRP20231458T HRP20231458T1 HR P20231458 T1 HRP20231458 T1 HR P20231458T1 HR P20231458T T HRP20231458T T HR P20231458TT HR P20231458 T HRP20231458 T HR P20231458T HR P20231458 T1 HRP20231458 T1 HR P20231458T1
Authority
HR
Croatia
Prior art keywords
alkyl
group
independently selected
cancer
cancer targeting
Prior art date
Application number
HRP20231458TT
Other languages
English (en)
Inventor
Izabela Tworowska
Nilesh Wagh
Ebrahim S. Delpassand
Federico ROJAS-QUIJANO
Paul Jurek
Garry E. Kiefer
Tania A. STALLONS
Amal SAIDI
Julien Torgue
Original Assignee
Radiomedix Inc.
Orano Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radiomedix Inc., Orano Med filed Critical Radiomedix Inc.
Publication of HRP20231458T1 publication Critical patent/HRP20231458T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Claims (13)

1. Kompozicija za ciljanje raka koja sadrži molekul Formule (I) ili njegovu farmaceutski prihvatljivu sol: Formula (I) M-Ch-L1-Tm, pri čemu M je radioizotop odabran iz grupe koja se sastoji od 212Pb i 203Pb; Ch je kelator koji ima strukturu Formule (V), [image] pri čemu R5, R6 i R8 su svaki nezavisno (C1-C6)alkil-C(=O)-N(-R25)-R26, R9, R10, R11, R12, R15, R16, R17, R18, R19, R20, R21, R22, R23 i R24 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, F, Cl i (C1-C6)alkila; R7 je odabran iz grupe koja se sastoji od (C1-C6)alkil-C(=O)-N(-R25)-R26 i L1; R13 i R14 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, F, Cl, (C1-C6)alkila, i L1; R25 i R26 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, (C1-C6)alkila i (C1-C6)alkil-C(=O)-OH; L1 je nezavisno odabran iz grupe koja se sastoji od (C1-C6)alkil-C(=O)-NH-(C1-C6)alkil-C(=O)-NH, (C1-C6)alkil-(C6H4)-NH-C(=S)-NH, C(-CO2H)-(C1-C6)alkil-(C6H4)-NH-C(=S)-NH, (C1-C6)alkil-C(=O)-NH, (C1-C6)alkil-C(=O)-(O-CH2-CH2)1-20-C(=O)-NH; i Tm ima strukturu Formule (VI), [image] pri čemu je R27 nezavisno odabran iz grupe koja se sastoji od CH2-OH i C(=O)-OH; i pod uslovom da samo jedan od R7, R13 ili R14 je L1.
2. Kompozicija za ciljanje raka prema patentnom zahtjevu 1, koja ima strukturu predstavljenu Formulom (VII) ili njena farmaceutski prihvatljiva sol: [image] pri čemu M je radioizotop odabran iz grupe koja se sastoji od 212Pb i 203Pb; R5, R6 i R8 su svaki nezavisno (C1-C6)alkil-C(=O)-N(-R25)-R26, R9, R10, R11, R12, R15, R16 , R17 , R18, R19, R20, R21, R22, R23 i R24 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, F, Cl i (C1-C6)alkila; R13 i R14 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, F, Cl i (C1-C6)alkila; R25 i R26 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, (C1-C6)alkila i (C1-C6)alkil-C(=O)-OH; L1 je nezavisno odabran iz grupe koja se sastoji od, i (C1-C6)alkil-C(=O)-NH-(C1-C6)alkil-C(=O)-NH, (C1-C6)alkil-(C6H4)-NH-C(=S)-NH, C(-CO2H)-(C1-C6)alkil-(C6H4)-NH-C(=S)-NH, (C1-C6)alkil-C(=O)-NH, i (C1-C6)alkil-C(=O)-(O-CH2-CH2)1-20-C(=O)-NH; i pri čemu je R27 nezavisno odabran iz grupe koja se sastoji od CH2-OH i C(=O)-OH.
3. Kompozicija za ciljanje raka prema patentnom zahtjevu 1, koja ima strukturu predstavljenu Formulom (VIII) ili njena farmaceutski prihvatljiva sol: [image] pri čemu M je radioizotop odabran iz grupe koja se sastoji od 212Pb i 203Pb; R5, R6 i R8 su svaki nezavisno (C1-C6)alkil-C(=O)-N(-R25)-R26, R9, R10, R11, R12, R15, R16 , R17 , R18, R19 > R20, R21, R22, R23 i R24 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, F, Cl i (C1-C6)alkila; R7 je, i (C1-C6)alkil-C(=O)-N(-R25)-R26, R13 je nezavisno odabranu iz grupe koja se sastoji od H, D, F, Cl i (C1-C6)alkila; R25 i R26 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, (C1-C6)alkila i (C1-C6)alkil-C(=O)-OH; L1 je (C1-C6)alkil-(C6H4)-NH-C(=S)-NH; i pri čemu je R27 nezavisno odabran iz grupe koja se sastoji od CH2-OH i C(=O)-OH.
4. Kompozicija za ciljanje raka prema patentnom zahtjevu 1, koja ima strukturu Formule (IX) ili njena farmaceutski prihvatljiva sol: [image] pri čemu M je radioizotop odabran iz grupe koja se sastoji od 212Pb, 203Pb; R5, R6 i R8 su svaki nezavisno (C1-C6)alkil-C(=O)-N(-R25)-R26, R9, R10, R11, R12, R15, R16 , R17 , R18, R19, R20, R21, R22, R23 i R24 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, F, Cl i (C1-C6)alkila; R13 i R14 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, F, Cl i (C1-C6)alkila; R25 i R26 su svaki nezavisno odabrani iz grupe koja se sastoji od H, D, (C1-C6)alkila, i (C1-C6)alkil-C(=O)-OH; i pri čemu je R27 nezavisno odabran iz grupe koja se sastoji od CH2-OH i C(=O)-OH.
5. Kompozicija za ciljanje raka prema patentnom zahtjevu 2, koja ima strukturu predstavljenu slijedećom formulom: [image]
6. Kompozicija raka prema patentnom zahtjevu 3, koja ima strukturu predstavljenu slijedećom formulom: [image]
7. Komplet za ciljanje raka za liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin, pri čemu komplet za ciljanje raka sadrži: kompoziciju za ciljanje raka prema bilo kojem prethodnom patentnom zahtjevu; i najmanje jedan od farmaceutski prihvatljivog pufera, antioksidansa i hvatača.
8. Komplet za ciljanje raka prema patentnom zahtjevu 7, pri čemu farmaceutski prihvatljiv pufer obuhvaća amonij acetatni pufer.
9. Komplet za ciljanje raka prema patentnom zahtjevu 8, koji sadrži 25-50µg kompozicije za ciljanje raka i 0.4M amonij acetatnog pufera.
10. Komplet za ciljanje raka prema bilo kojem od patentnih zahtjeva 7 do 9, pri čemu antioksidans uključuje askorbinsku kiselinu, gentizinsku kiselinu, etanol ili njihove kombinacije.
11. Komplet za ciljanje raka prema bilo kojem od patentnih zahtjeva 7 do 10, pri čemu je hvatač onaj odabran iz grupe koja se sastoji od: dietilentriamin penta-octena kiselina; etilendiamintetraoctena kiseline; 1,4,7,10-tetraazaciklododekan-1,4,7,10-tetraoctene; i njihovih kombinacija.
12. Kompozicija za ciljanje raka prema bilo kojem prethodnom patentnom zahtjevu za primjenu kao lijek za liječenje kancerogenih stanica koje prekomjerno eksprimiraju receptore za somatostatin kod pacijenta kome je to potrebno.
13. Kompozicija za ciljanje raka prema patentnom zahtjevu 12, pri čemu je kompozicija za primjenu sa najmanje jednim spojem protiv raka u farmaceutski prihvatljivom nosaču, pri čemu najmanje jedan spoj protiv raka uključuje Aldesleukin; Alemtuzumab; alitretinoin; alopurinol; altretamin; amifostin; anastrozol; arsen trioksid; Asparaginazu; živ BCG; beksaroten kapsule; beksaroten gel; bleomicin; busulfan intravenozno; busulfan oralni; kalusteron; kapecitabin; karboplatin; karmustin; karmustin sa Polifeprosan 20 implantatom; celekoksib; klorambucil; cisplatin; kladribin; ciklofosfamid; citarabin; citarabin liposomski; dakarbazin; daktinomicin, aktinomicin D; Darbepoetin alfa; daunorubicin liposomski; daunorubicin, daunomicin; Denileukin diftitoks, deksrazoksan; docetaksel; doksorubicin; doksorubicin liposomski; Dromostanolon propionat; Elliott-ovu B otopinu; epirubicin; Epoetin alfa estramustin; etopozidfosfat; etopozid (VP-16); eksemestan; Filgrastim; floksuridin (intraarterijski); fludarabin; fluorouracil (5-FU); fulvestrant; gemcitabin; gemtuzumab ozogamicin; glivec (imatinib); goserelin acetat; hidroksiureu; Ibritumomab Tiuksetan; idarubicin; ifosfamid; imatinib meziflat; Interferon alfa-2a; Interferon alfa-2b; irinotekan; letrozol; leukovorin; levamisol; lomustin (CCNU); mekloretamin (dušikov iperit); megestrol acetat; melfalan (L-PAM); merkaptopurin (6-MP); mesna; metotreksat; metoksalen; mitomicin C; mitotan; mitoksantron; nandrolon fenpropionat; Nofetumomab; LOddC; Oprelvekin; oksaliplatin; paklitaksel; pamidronat; pegademaza; Pegaspargaza; Pegfilgrastim; pentostatin; pipobroman; plikamicin; mitramicin; porfimer natrij; prokarbazin; kinakrin; Rasburikaza; Rituksimab; Sargramostim; streptozocin; surafenib; talbuvidin (LDT); talk; tamoksifen; tarceva (erlotinib); temozolomid; tenipozid (VM-26); testolakton; tioguanin (6-TG); tiotepa; topotekan; toremifen; Tositumomab; Trastuzumab; tretinoin (ATRA); Uracil iperit; valrubicin; valtorcitabin (monoval LDC); vinblastin; vinorelbin; zoledronat; ili njihovu mješavinu.
HRP20231458TT 2017-01-12 2018-01-12 Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima HRP20231458T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445541P 2017-01-12 2017-01-12
PCT/US2018/013640 WO2018132751A1 (en) 2017-01-12 2018-01-12 Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
EP18703122.4A EP3568205B1 (en) 2017-01-12 2018-01-12 Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes

Publications (1)

Publication Number Publication Date
HRP20231458T1 true HRP20231458T1 (hr) 2024-05-10

Family

ID=61157311

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231458TT HRP20231458T1 (hr) 2017-01-12 2018-01-12 Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima

Country Status (20)

Country Link
US (1) US11541133B2 (hr)
EP (1) EP3568205B1 (hr)
JP (1) JP7084417B2 (hr)
KR (1) KR102296752B1 (hr)
CN (1) CN110678227B (hr)
AU (1) AU2018207190B2 (hr)
CA (1) CA3050094C (hr)
DK (1) DK3568205T3 (hr)
ES (1) ES2960030T3 (hr)
FI (1) FI3568205T3 (hr)
HR (1) HRP20231458T1 (hr)
HU (1) HUE063981T2 (hr)
IL (1) IL268012B (hr)
LT (1) LT3568205T (hr)
PL (1) PL3568205T3 (hr)
PT (1) PT3568205T (hr)
RS (1) RS64815B1 (hr)
SI (1) SI3568205T1 (hr)
SM (1) SMT202300398T1 (hr)
WO (1) WO2018132751A1 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019287595B2 (en) * 2018-04-27 2024-10-31 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
EP4096723A1 (en) 2020-01-29 2022-12-07 University of Iowa Research Foundation Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers
CA3176404A1 (en) * 2020-04-24 2021-10-28 Ebrahim S. Delpassand Composition, kit and method for diagnosis and treatment of prostate cancer
EP3973999A1 (en) * 2020-09-28 2022-03-30 Orano Med Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
US20230382819A1 (en) * 2020-10-14 2023-11-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Processes for synthesis of alpha-emitting radiopharmaceuticals
NL2028075B1 (en) * 2021-04-26 2022-11-03 Alphathera Ag Targeting system for cancer comprising a radioisotope
CN113277989B (zh) * 2021-04-27 2022-05-31 中南大学湘雅医院 一种68Ga标记的分子探针、制备方法及其应用
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
EP4282439A1 (en) 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers
NL2033489B1 (en) 2022-11-09 2024-05-28 Coretag Ip B V Targeting system for cancer treatment
WO2024245421A1 (en) * 2023-05-31 2024-12-05 Full-Life Technologies Hk Limited Radioligands for targeting cell surface receptors and uses thereof
CN117224713A (zh) * 2023-06-28 2023-12-15 北京先通国际医药科技股份有限公司 212Pb-DOTATATE在制备用于治疗生长抑素受体阳性的胃肠胰腺神经内分泌瘤的药物中的用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004017D0 (en) 1990-02-22 1990-04-18 Krenning Eric P Improvements in or relating to organic compounds
US6017512A (en) * 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US7361346B1 (en) 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6866837B2 (en) 1998-06-05 2005-03-15 Mallinckrodt Inc. Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
US6926883B1 (en) 1999-06-29 2005-08-09 Mallinckrodt Inc Group (VII) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
ATE272074T1 (de) 2000-04-26 2004-08-15 Biosynthema Inc An neuropeptide gebundenes rgd (arg-gly-asp)
WO2002022000A2 (en) 2000-09-15 2002-03-21 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
JP5398945B2 (ja) 2001-04-23 2014-01-29 マリンクロッド エルエルシー ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体
EP1283216A1 (en) 2001-08-10 2003-02-12 Mallinckrodt Inc. Somatostatin analogues binding to all somatostatin receptor subtypes and their use
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7122622B2 (en) * 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
DE602005025659D1 (hr) * 2004-09-23 2011-02-10 Guerbet Sa
US20070025910A1 (en) * 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
US8097237B2 (en) 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
EP1988925A2 (en) 2006-02-24 2008-11-12 Mallinckrodt, Inc. Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
KR20080108989A (ko) 2006-03-14 2008-12-16 말린크로트, 인코포레이티드 테트라아자거대고리 유도체의 금속 착체
US20160045626A1 (en) * 2007-01-11 2016-02-18 Immunomedics, Inc. Methods and Compositions for Improved Labeling of Targeting Peptides
WO2008119036A2 (en) 2007-03-27 2008-10-02 Radiomedix Inc. Compositions for targeted imaging and therapy
US20100316566A1 (en) 2008-02-27 2010-12-16 Radiomedix Inc. Radiolabeled hedgehog derivatives for imaging and therapy
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
US8623322B2 (en) 2008-06-13 2014-01-07 Stc.Unm Non-invasive diagnostic agents and methods of diagnosing infectious disease
US8858916B2 (en) 2008-09-30 2014-10-14 Mallinckrodt Llc Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent
EP2456472B1 (en) 2009-07-22 2024-03-27 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
WO2011066521A2 (en) 2009-11-30 2011-06-03 Stc. Unm Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
US20120052008A1 (en) 2010-08-25 2012-03-01 Yuri Mackeyev Nanostructures comprising radioisotopes and/or metals
US9180214B1 (en) 2011-04-22 2015-11-10 Stc.Unm Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
PL2721045T3 (pl) 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
US10159759B2 (en) * 2011-08-31 2018-12-25 Somscan Aps Pet tracer for imaging of neuroendocrine tumors
CA2858964A1 (en) * 2011-12-13 2013-06-20 Nordic Nanovector As Chimeric therapeutic anti-cd37 antibodie hh1
ES2745635T3 (es) 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR
ES2617225T3 (es) 2012-10-02 2017-06-15 Guerbet Proceso para la preparación de ligandos y quelatos de poliazacarboxilatos macrocíclicos
US20140147381A1 (en) * 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
CA2915708C (en) 2013-06-18 2018-02-06 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
US20150157742A1 (en) 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
EP3283128A4 (en) * 2015-02-27 2019-01-16 Rochester Institute of Technology TRANSMETALIZATION PROCEDURE FOR SYNTHESIS OF PET AND SPECT CONTRASTANTS
JP6959142B2 (ja) * 2015-05-06 2021-11-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｍｃ１ｒを標的とする放射線療法用作用物質およびコンパニオンイメージング作用物質
HUE034806T2 (en) * 2015-07-03 2018-02-28 Oncoinvent As Radiotherapy Particles and Suspensions
CN106084005B (zh) * 2016-06-15 2020-02-14 广州军区广州总医院 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
EP4096723A1 (en) * 2020-01-29 2022-12-07 University of Iowa Research Foundation Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers

Also Published As

Publication number Publication date
CN110678227A (zh) 2020-01-10
AU2018207190B2 (en) 2020-12-03
EP3568205A1 (en) 2019-11-20
IL268012B (en) 2021-12-01
JP7084417B2 (ja) 2022-06-14
SMT202300398T1 (it) 2024-01-10
EP3568205B1 (en) 2023-08-16
JP2020505445A (ja) 2020-02-20
CN110678227B (zh) 2023-03-21
WO2018132751A1 (en) 2018-07-19
IL268012A (en) 2019-09-26
CA3050094A1 (en) 2018-07-19
CA3050094C (en) 2024-01-02
DK3568205T3 (da) 2023-10-09
KR102296752B1 (ko) 2021-09-02
RS64815B1 (sr) 2023-12-29
FI3568205T3 (fi) 2023-11-01
AU2018207190A1 (en) 2019-08-29
ES2960030T3 (es) 2024-02-29
PT3568205T (pt) 2023-10-26
LT3568205T (lt) 2024-02-12
HUE063981T2 (hu) 2024-02-28
KR20200016196A (ko) 2020-02-14
US11541133B2 (en) 2023-01-03
PL3568205T3 (pl) 2024-03-18
US20190336623A1 (en) 2019-11-07
SI3568205T1 (sl) 2023-12-29

Similar Documents

Publication Publication Date Title
HRP20231458T1 (hr) Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
ES2991555T3 (es) Composiciones y métodos para inhibir la actividad de la arginasa
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
DE3750436T2 (de) Halbsynthetisches Erythromycin-Antibiotikum.
HRP20210848T1 (hr) Sastavi i postupci za sprječavanje aktivnosti arginaze
JP2020504735A5 (hr)
PE20130151A1 (es) Sintesis estereoselectiva de activos que contienen fosforo
JP2020514271A5 (hr)
BR112016003348A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
MX376742B (es) Conjugados de cisteamina y ácidos grasos y su uso como activadores de la autofagia
IN2014CN00712A (hr)
ES2984594T3 (es) Inhibidores de metaloproteinasa de matriz (MMP) y métodos de uso de los mismos
RU2016138027A (ru) Лечение состояний, ассоциированных с гиперинсулинемией
JP2013510904A5 (hr)
WO2014078295A8 (en) Gemcitabine prodrugs and uses thereof
JP2014510727A5 (hr)
RU2019120181A (ru) Антимикробные пептиды
NZ563686A (en) Methods of treating cancer and other conditions or disease states using LFMAU and LDT
JP2018510175A5 (hr)
WO2009156182A2 (de) Uracilderivate und deren verwendung
RU2014133390A (ru) Производные изохинолина и нафтиридина
JP2017531013A5 (hr)
CA2797281A1 (en) Aza-indole derivatives useful as modulators of faah
ES2320649T3 (es) Pirimidin-sulfamidas y su uso como antagonistas de receptores de endotelina.
JP5461989B2 (ja) ヌクレオシド類、これらを含有する薬物とその使用